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A B S T R A C T
The cytokine transforming growth factor beta 1 (TGF-β1) has been widely implicated in the develop-
ment and progression of renal ﬁbrosis in chronic kidney disease (CKD) in humans and in experimental
models. The aims of this study were to assess the association between urinary active TGF-β1 and (a) de-
velopment of CKD in a cross-sectional study, (b) deterioration of renal function over 1 year in a longitudinal
study, and (c) renal histopathological parameters in cats. A human active TGF-β1 ELISA was validated
for use in feline urine.
Cross-sectional analysis revealed no signiﬁcant difference in urinary active TGF-β1:creatinine ratio
(aTGF-β1:UCr) between groups with differing renal function. Longitudinally, non-azotaemic cats that de-
veloped CKD demonstrated a signiﬁcant (P = 0.028) increase in aTGF-β1:UCr approximately 6 months
before the development of azotaemia, which remained elevated (P = 0.046) at diagnosis (approximately
12 months prior, 8.4 pg/mg; approximately 6 months prior, 22.2 pg/mg; at CKD diagnosis, 24.6 pg/mg).
In the histopathology study, aTGF-β1:UCr was signiﬁcantly higher in cats with moderate (P = 0.02) and
diffuse (P = 0.005) renal ﬁbrosis than in cats without ﬁbrosis. Cats with moderate renal inﬂammation had
signiﬁcantly higher urinary active aTGF-β1 concentrations than cats with mild (P = 0.035) or no inﬂam-
matory change (P = 0.004). The parameter aTGF-β1:UCr was independently associated with Log urine
protein:creatinine ratio in a multivariable analysis of clinicopathological parameters and interstitial ﬁ-
brosis score in a multivariable analysis of histopathological features. These results suggest that urinary
aTGF-β1 reﬂects the severity of renal pathology. Increases in urinary aTGF-β1 followed longitudinally
in individual cats may indicate the development of CKD.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Chronic kidney disease (CKD) is common in ageing cats, with a
prevalence of 28–50% (Lulich et al., 1992; Marino et al., 2014). In
most cases, the inciting cause is unknown and the predominantmor-
phological diagnosis is chronic tubulointerstitial inﬂammation and
ﬁbrosis (DiBartola et al., 1987; Chakrabarti et al., 2013).
The cytokine transforming growth factor beta one (TGF-β1) is
themost studied pro-ﬁbroticmediator in human and experimentally-
induced kidney disease. TGF-β1 is secreted as an inactive precursor
combined with the latency associated pro-peptide and latent TGF-β
binding protein as the large latent complex (LLC). The active TGF-
β1 peptidemust be liberated from the LLC to exert a biological effect,
a process that is initiated by a variety of molecules implicated in
extra-cellular matrix (ECM) disruption (Annes et al., 2003). The TGF-
β1 pathway integrates the effects of many other ﬁbrogenic factors
(Liu, 2006) and is upregulated by various renal insults. The pro-
ﬁbrotic effects of TGF-β1 include induction of myoﬁbroblast
formation (Serini et al., 1998; He et al., 2013;Wu et al., 2013), direct
stimulation of ECM-related gene transcription (Border and Noble,
1993) and reduced ECMdegradation (Edwards et al., 1987; Krag et al.,
2005). Urinary total TGF-β1 excretion increases in various human
renal diseases (De Muro et al., 2004) as a result of increased renal
production (Sharma et al., 1997).
Previous studies have demonstrated that total TGF-β1 (normalised
to urinary creatinine) is also present in increased concentrations in
the urine of cats with CKD (Arata et al., 2005; Habenicht et al., 2013),
suggesting urinary TGF-β1may be a useful biomarker of renal injury
in feline CKD. However, there are no published studies examining
urinary TGF-β1 prior to the diagnosis of azotaemic feline CKD or at-
tempts to correlate urinary TGF-β1 with renal histopathology.
In this study, we hypothesised that urinary active TGF-β1 could
be used as a biomarker of renal ﬁbrosis and progressive renal disease
in cats. To address this hypothesis, an assay for urinary active TGF-
β1 was validated and the relationships between azotaemic CKD and
renal ﬁbrosis were assessed. Three analyses were undertaken: a
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cross-sectional study; a longitudinal study; and a study correlat-
ing urinary TGF-β1 with renal histopathology.
Materials and methods
Case selection
The records from two ﬁrst-opinion practices were searched for cats >9 years old
with and without renal azotaemia. Renal azotaemia was deﬁned as a plasma cre-
atinine concentration of >177 μmol/L with concurrent urine speciﬁc gravity of <1.035.
Cats with hyperthyroidism (plasma TT4 >40 nmol/L), urinary tract infection, or other
systemic disease diagnosed within the follow-up period were excluded.
For the cross-sectional study, cases were classiﬁed based upon baseline status
and subsequent renal function, resulting in three groups: non-azotaemic cats that
remained non-azotaemic for 24 months (NA), non-azotaemic cats that developed
azotaemia within 24 months (NA-A), and cats with renal azotaemia at baseline (A).
For the longitudinal study, cats with three urine samples approximately 6months
apart were identiﬁed and classiﬁed into three groups: non-azotaemic cats that re-
mained non-azotaemic (stable group), non-azotaemic cats that developed azotaemia
after 11–15 months (developed azotaemia group) and azotaemic cats with progres-
sion of CKD after 11–15 months (progressive CKD group). Progression was deﬁned
as a repeatable >25% increase in plasma creatinine from baseline.
The renal pathology study included cats of any age with and without CKD if his-
topathological data were available, and a urine sample was collected within 3months
before death. Renal tissue was ﬁxed in 10% neutral buffered formalin and histo-
pathological data were available from a previous study where transverse sections
were scored for a variety of pathological features (Chakrabarti et al., 2013). The sec-
tions were scored for interstitial ﬁbrosis and inﬂammation as follows: 0, none or
rare small foci; 1, mild or scattered multifocal areas affecting <5% of the section; 2,
moderate ﬁbrosis/inﬂammation affecting 25–50% of the section; 3, diffuse or co-
alescing ﬁbrosis/inﬂammation. Glomerulosclerosis was scored as follows: 0, normal
(matrix could encircle nomore than 1 nucleus); 1, mild (matrix could surround several
nuclei but not extend to peripheral capillary loops); 2, moderate (matrix expan-
sion involving peripheral capillary loops and affecting <50% of the glomerulus); and
3, severe (matrix expansion affecting >50% of the glomerulus). Mean glomerular
volume was calculated from the cross-sectional area of 20 randomly selected non-
obsolescent outer cortical glomerular tufts.
Clinicopathological data
Blood and urine samples were obtained by jugular venepuncture and
cystocentesis, respectively. Urine sediment examination was performed in-house.
Samples with evidence of urinary tract infection (bacturia/pyuria or positive urine
culture, which was routinely performed when infection was suspected) were ex-
cluded. Plasma biochemistry, urine creatinine and urine protein were measured at
an external laboratory (IDEXX Laboratories). Residual samples of urine and plasma
were retained for research use with owner informed consent. When animals were
euthanased and a post-mortem examinationwas undertaken, owner informed consent
was obtained. The project protocol, owner information document and informed
consent forms were approved by the RVC’s Ethics andWelfare Committee (URN 2013
1258, 2 December 2013).
All urine samples were centrifuged and stored at −80 °C. TGF-β1 concentra-
tions were normalised as a urine TGF-β1:urine creatinine ratio (TGF-β1:UCr). Systolic
blood pressure (SBP) was measured by the Doppler method as per ACVIM consen-
sus guidelines (Brown et al., 2007) and mean SBP calculated from ﬁve readings.
TGF-β1 assay validation
Four enzyme-linked immunoassay (ELISA) kits underwent validation for themea-
surement of TGF-β1 in feline urine: Multispecies total TGF-β1 (Invitrogen), Human
Free Active TGF-β1 (BioLegend), Mouse Latent TGF-β (BioLegend) and Human Latent
TGF-β (BioLegend). Precision and reproducibility were determined for samples with
a range of TGF-β1 concentrations by calculating inter- and intra-assay coeﬃcients
of variation (CV) where assays detected measurable feline TGF-β1. Speciﬁcity was
assessed by evaluating three serial dilutions of samples along the standard curve.
The spike-and-recovery of the Free Active TGF-β1 assay was assessed via spiking
urine samples with recombinant active TGF-β1 (Part #78251, BioLegend) at high
(250 pg/mL), medium (125 pg/mL) and low (62.5 pg/mL) concentrations and com-
paring results to expected values. The lower limit of detection (LoD) was established
by assaying multiple wells (n = 8) of the lowest (0 pg/mL) standard and taking four
standard deviations above the mean value (Armbruster and Pry, 2008).
Statistical analysis
Statistical analysis was carried out using computer software (IBM SPSS Statis-
tics for Windows, Version 20.0). Data were assessed visually for normality. Urinary
active TGF-β1 demonstrated a non-Gaussian distribution. Comparisons between
groups in the cross-sectional and renal pathology studyweremade using the Kruskal–
Wallis test, with post-hoc pairwise Mann–Whitney U tests where appropriate, and
correlations between variables were examined using Spearman’s correlation coef-
ﬁcient. Comparisons between visits within groups in the longitudinal study were
made using the Friedman test with post-hoc pairwiseWilcoxon sign rank tests where
appropriate. Signiﬁcance was set at P < .05. Results are reported as median values
(range) or mean ± standard deviation (SD), as appropriate.
Univariable linear regression analyses were performed to identify clinicopatho-
logical (creatinine, urea, phosphate, PCV, potassium, urine protein:creatinine ratio
[UPC]) and histopathological (interstitial ﬁbrosis score, inﬂammation score, glo-
merulosclerosis score, glomerular volume) predictors of urinary TGF-β1 concentration
in the cross-sectional and renal pathology studies, respectively. Variables signiﬁ-
cant at the 20% level were included in two separate backward selection multivariable
analyses with ﬁnal signiﬁcance set at the 5% level. Variables were log-transformed
if necessary to meet the assumptions for multivariable linear regression.
Results
Validation of the ELISA
TheMultispecies Total TGF-β1,Mouse Latent TGF-β, Human Latent
TGF-β ELISA kits did not detect TGF-β in feline urine. The Free Active
TGF-β1 (aTGF-β1) kit detectedmeasurable levels of cytokine in feline
urine and underwent further validation. Intra-assay CV for samples
measuring 18, 20, 28 and 62 pg/mL aTGF-β1 (n = 4) was 2.3–7.5%.
Inter-assay CV for samples measuring 26, 62, 118 and 183 pg/mL
aTGF-β1 (n = 4) was 4.7–20.9%. Dilutional linearity indicated a mean
recovery of 91.6% ± 17.5% (n = 4). Spiking urine samples with exog-
enous recombinant aTGF-β1 produced mean recovery values of
110.9 ± 15.9% (n = 3), 118.5 ± 11.3% (n = 3) and 117.1 ± 9.5% (n = 3)
for the low, medium and high spikes, respectively. These recovery
values were slightly greater than when spiking sample diluent, sug-
gesting a minor matrix effect of feline urine. The lower LoD was
2.9 pg/mL; therefore, samples assayedwith an active TGF-β1 < 2.9 pg/
mL were assigned the arbitrary value 1.5 pg/mL (US EPA, 2000).
Urinary active TGF-β1 cross-sectional study
Sixty-seven cats were included in the cross sectional study. These
included 33 male neutered (MN) and 34 female neutered (FN) cats
of mean age 13.5 (±2.4) years. There was no difference in aTGF-
β1:UCr between groups with differing renal function (NA [n = 20],
17.6 pg/mg [1.5–39.0]; NA-A [n = 23], 14.5 pg/mg [1.5–81.2]; A [n = 24],
21.2 pg/mg [1.5–185.0]; Fig. 1). However, one cat in the NA-A group
and three cats in the A group demonstrated an aTGF-β1:UCr at least
Fig. 1. Scatterplot illustrating urinary active transforming growth factor beta 1:urinary
creatinine ratio (TGF-β1:UCr) in non-azotaemic cats that remained non-azotaemic
for 24 months (NA), non-azotaemic cats that developed azotaemia within 24 months
(NA-A) and cats that were azotaemic at baseline (A). The line represents the median.
The Kruskal–Wallis test found no signiﬁcant difference in TGF-β1:UCr between groups
(P = 0.35).
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50% greater than the highest measured value in the NA group. Con-
sidering the whole study population, the only variable correlated
with aTGF-β1:UCr was UPC, which showed a weak positive corre-
lation (r = 0.257, P = 0.036). When separated by group, the only
variables signiﬁcantly (and positively) correlated with TGF-β1:UCr
were age (r = 0.49, P = 0.017), mean SBP (r = 0.45, P = 0.029) and PCV
(r = 0.42, P = 0.047) in the NA group, and UPC in the A group of cats
(r = 0.42, P = 0.04).
Prior to linear regression, aTGF-β1:UCr, creatinine and UPC were
log transformed due to non-Gaussian distribution. Clinicopatho-
logical predictors of logaTGF-β1:UCr included in the multivariable
model are presented in Table 1. LogUPC was the only independent
clinicopathological predictor of logaTGF-β1:UCr (P = 0.014).
Urinary active TGF-β1 longitudinal study
Eighteen cats were included in the longitudinal study, with six
cats in each group. These included nineMN and nine FN cats of mean
age 13.8 (±2.4) years. Urine samples from three time-points were
available – baseline, 4–9 months, and 11–15 months. In the stable
renal function group, aTGF-β1:UCr did not change over the course
of 1 year (Fig. 2). The developed azotaemia group demonstrated a
signiﬁcant (P = 0.028) 2.6-fold increase in aTGF-β1:UCr approxi-
mately 6months prior to development of azotaemia, which remained
elevated (P = 0.046) at the point of diagnosis of azotaemia. In the
progressive CKD group, the aTGF-β1:UCr did not change signiﬁ-
cantly prior to progression of renal disease.
Correlation of urinary active TGF-β1 with post-mortem renal
pathology
Fifty-nine cats were included in the pathology study (39MN, one
male entire and 19 FN; mean age 13.9 [±5.2] years). Two cats with
histopathological diagnoses of papillary necrosis and hydronephro-
sis, respectively, demonstrated urinary aTGF-β1 concentrations above
the highest standard (500 pg/mL) and were assigned a value of
500 pg/mL for the purposes of analysis.
The parameter aTGF-β1:UCr was moderately correlated with in-
terstitial ﬁbrosis score (r = 0.416, P = 0.001) and weakly correlated
with inﬂammation score (r = 0.385, P = 0.003). When grouped by in-
terstitial ﬁbrosis score, cats with scores of 2 (P = 0.02) and 3
(P = 0.005) had signiﬁcantly higher aTGF-β1:UCr concentrations than
cats that scored 0 for interstitial ﬁbrosis (Fig. 3). When grouped by
inﬂammation score, cats that scored ≥2 had signiﬁcantly higher aTGF-
β1:UCr concentrations than cats that scored 1 (P = 0.035) or 0
(P = 0.004; Fig. 4). The parameter aTGF-β1:UCr and mean glomeru-
lar volume were log transformed prior to linear regression due to
non-Gaussian distribution. Histopathological predictors of LogaTGF-
β1:UCr included in themultivariable model are presented in Table 2.
Fibrosis score was the only independent histopathological predic-
tor of LogaTGF-β1:UCr (P = 0.008).
Discussion
The Free Active TGF-β1 ELISA was the only assay investigated,
which detected measurable levels of cytokine, and to our knowl-
edge, this study is the ﬁrst to measure concentrations of aTGF-β1
in feline urine. The assay demonstrated acceptable precision and
Table 1
Univariable and multivariable linear regression to identify predictors of urinary active transforming growth factor beta 1:urinary creatinine ratio (TGF-β1:UCr) in the cross-
sectional study. Parameters signiﬁcant at the <0.2 level are presented below. LogUPC was the only independent predictor in the multivariable analysis (P = 0.014).
Variable Univariable analysis Multivariable analysis
B SE P 95% CI for B B SE P 95% CI for B
LogUPC 0.553 0.218 0.014 0.117–0.989 0.553 0.218 0.014 0.117–0.989
SBP 0.004 0.002 0.084 −0.001 to 0.009
Age 0.055 0.025 0.03 0.006–0.105
B, coeﬃcient; SE, standard error; CI, conﬁdence interval.
Fig. 2. Box and whisker plot illustrating urinary active transforming growth factor
beta 1:urinary creatinine ratio (TGF-β1:UCr) in cats with stable renal function over
11–15 months, cats that developed azotaemia at the 11–15 month time-point and
cats with progressive CKD at 11–15 months. The boxes represent 25th and 75th per-
centiles, the central lines represent the median values and the whiskers represent
the range. The Friedman test and Wilcoxon sign rank test demonstrated that cats
that developed azotaemia demonstrated a signiﬁcant increase in TGF-β1:UCr ap-
proximately 6 months prior to the development of azotaemia (P = 0.028), which was
sustained at the point of demonstration of azotaemia (P = 0.046; *P < 0.05).
Fig. 3. Box and whisker plot illustrating urinary active transforming growth factor
beta 1:urinary creatinine ratio (TGF-β1:UCr) of cats in the renal pathology study,
grouped by severity of renal interstitial ﬁbrosis. The Kruskal–Wallis test and Mann–
Whitney U test demonstrated that cats with moderate ﬁbrosis affecting 25–50% of
the section (score 2) and diffuse/coalescing ﬁbrosis (score 3) had signiﬁcantly higher
urinary TGF-β1:UCr ratios than cats with no ﬁbrosis.*P < 0.05; **P < 0.01.
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reproducibility, speciﬁcity and spike-recovery, supporting its use in
feline urine, although a western blot would be required to conﬁrm
cross-reactivity. The Multispecies Total TGF-β1 assay used previ-
ously to measure feline urinary Total TGF-β1 (Arata et al., 2005;
Habenicht et al., 2013) did not detect measurable concentrations
of feline total TGF-β1 in the present study.
The cross-sectional study failed to detect differences in urinary aTGF-
β1 concentration between groupswith differing renal function. One cat
that becameazotaemic and three catswithpre-existing azotaemiadem-
onstrated elevated concentrations of urinary aTGF-β1, but themajority
had low concentrations comparable to non-azotaemic cats. There is
limited information on urinary aTGF-β1 in the veterinary andmedical
literature. A previous study in humans detected urinary aTGF-β1 in 25%
of patients with active nephropathy subsequent to allograft dysfunc-
tion, but aTGF-β1was undetectable in the urine of patientswith normal
renal function (Rogier et al., 2005). In contrast, themajority of healthy
geriatric cats in this study demonstrated low, but detectable, concen-
trations of aTGF-β1. This discrepancy could be due to the advanced age
of the healthy control group in the current study. Renal TGF-β1 activ-
ity is upregulated in aged rodents (Ruiz-Torres et al., 1998) and the same
may be true in cats. However, undetected early renal dysfunction in the
non-azotaemic group cannot be discounted, despite the 2-year follow-
up period.
The ﬁndings of this study regarding urinary aTGF-β1 contrast with
two previously published feline studies where total TGF-β1wasmea-
sured and increased urinary concentrations were present in cats with
CKD (Arata et al., 2005; Habenicht et al., 2013). The reason for this
discrepancy may be associated with the form of TGF-β1 mea-
sured. The concentration of aTGF-β1 in biological ﬂuids is very low
compared to total TGF-β1 (Khan et al., 2012) and the two formsmay
not correlate with each other. While CKD results in increased urinary
total TGF-β1 concentrations, as demonstrated previously, the in-
crease may be primarily attributable to increased excretion of the
latent complex, rather than the active peptide. Measurement of aTGF-
β1 is potentially a more valid estimation of kidney TGF-β1 activity
than total TGF-β1, as liberation of aTGF-β1 from the LLC is a pivotal
point of control in the regulation of TGF-β1 signalling (Annes et al.,
2003). Furthermore, aTGF-β1 has a short plasma half-life, under-
going rapid hepatic clearance (Wakeﬁeld et al., 1990), and thus
urinary aTGF-β1 is likely to originate locally.
CKD in cats might not induce increased TGF-β1 activity within
renal tissue. This would be unexpected, as alterations within the
renal micro-environment that occur within the diseased feline
kidney, such as increased single nephron ﬁltration rate (Brown and
Brown, 1995), oxidative stress (Keegan and Webb, 2010) and RAAS
activation (Watanabe and Mishina, 2007), upregulate TGF-β1 pro-
duction and activation in other species (Wolf, 2006; Shin et al., 2008;
Rohatgi and Flores, 2010) . Furthermore, this assumption was not
supported by the longitudinal study. Non-azotaemic cats that de-
veloped CKD demonstrated a sustained increase in urinary aTGF-
β1 excretion approximately 6 months prior to the deterioration of
renal function, whereas excretion of aTGF-β1 in non-azotaemic cats
with stable renal function and azotaemic cats with progressive CKD
did not change over 12 months. Although there was a signiﬁcant
overlap between groups, suggesting a high level of individual vari-
ation in aTGF-β1 excretion, this ﬁnding suggests that elevations in
urinary aTGF-β1 might only be identiﬁed during certain phases of
CKD pathogenesis, rather than being consistently present in all cats
with CKD.
LogUPC was the only independent clinicopathological predic-
tor of urinary aTGF-β1 concentration. In addition, the four cats in
the cross-sectional study with elevated aTGF-β1 were either
proteinuric or borderline proteinuric. This is in accordance with the
medical literature, where urinary TGF-β1 excretion correlated with
degree of proteinuria in various glomerulonephropathies (Ellis et al.,
1998; Shaker and Sadik, 2013). UPC in cats is an independent pre-
dictor of CKD progression (Chakrabarti et al., 2012) and survival
(Syme et al., 2006), and if increased urine protein is a contributing
factor to, rather than a marker of, progressive renal damage, some
of the negative effects could be mediated by the upregulation of in-
ﬂammatory or pro-ﬁbrotic mediators, such as TGF-β1. Alternatively,
increased urinary concentration of TGF-β1 in proteinuric cats may
reﬂect increased fractional excretion of serum TGF-β1 due to the
compromised ﬁltration barrier in these cats.
To the authors’ knowledge, this is the ﬁrst study to correlate
urinary TGF-β1 with renal histopathology in cats. Cats with higher
interstitial ﬁbrosis and inﬂammation scores had signiﬁcantly higher
urinary aTGF-β1 concentrations than cats where no inﬂammation
or ﬁbrosis was present. Interstitial ﬁbrosis was the only histopatho-
logical variable independently associated with urinary aTGF-β1. This
agrees with previous studies in humans with glomerular diseases,
where urinary TGF-β1 reﬂected grade of interstitial ﬁbrosis and
Fig. 4. Box and whisker plot illustrating urinary active transforming growth factor
beta 1:urinary creatinine ratio (TGF-β1:UCr). The Kruskal–Wallis test and Mann–
Whitney U test demonstrated that cats with moderate inﬂammation affecting
25–50% of the section and above (score 2+) had signiﬁcantly higher urinary TGF-
β1:UCr ratios than cats with no inﬂammatory inﬁltrate andmild inﬂammation (score
1). *P < 0.05; **P < 0.01.
Table 2
Univariable and multivariable linear regression to identify independent histopathological predictors of urinary active transforming growth factor beta 1:urinary creatinine
ratio (TGF-β1:UCr) in the renal pathology study. Parameters signiﬁcant at the <0.2 level are presented below. Interstitial ﬁbrosis score was the only independent predictor
in the multivariable analysis (P = 0.008).
Variable Univariable analysis Multivariable analysis
B SE P 95% CI for B B SE P 95% CI for B
Interstitial ﬁbrosis 0.199 0.073 0.008 0.054–0.345 0.199 0.073 0.008 0.054–0.345
Interstitial inﬂammation 0.243 0.098 0.016 0.046–0.441
Glomerulosclerosis 0.278 0.168 0.103 −0.058 to 0.614
B, coeﬃcient; SE, standard error; CI, conﬁdence interval.
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inﬂammation (Honkanen et al., 1997;Murakami et al., 1997). Overall,
evidence from human studies suggests that severe urinary total TGF-
β1 elevations are associated with acute phases of tissue damage and
inﬂammatory glomerular conditions rather than primarily inter-
stitial or slowly progressive diseases (DeMuro et al., 2004; Dukanovic
et al., 2009). When renal biopsies are submitted for histopatho-
logical examination from cats with CKD, a histopathological diagnosis
of tubulointerstitial ﬁbrosis is usually made (Chakrabarti et al., 2013),
and a substantial number of cats with CKD have slowly progres-
sive or non-progressive disease (Chakrabarti et al., 2012). Additionally,
where progression does take place, it may occur in a stepwise rather
than a linear fashion (Elliott et al., 2003). These factors might explain
why the majority of cats in our renal pathology and cross-sectional
studies did not demonstrate substantial elevations of urinary aTGF-
β1. The two cats in the renal pathology studywith extreme elevations
of urinary aTGF-β1 had evidence of acute renal insult, which further
supports this hypothesis.
A limitation of the renal pathology study was the varying time
(0–90 days) between urine sample collection and post-mortem ex-
amination. Acute changes in urinary aTGF-β1 prior to death could
have been missed because of this variation. A limitation of all three
studies was the use of creatinine as an indicator of renal function.
Serum creatinine is an insensitive marker of mild to moderate re-
ductions in glomerular ﬁltration rate (Swan, 1997), and pathological
changes in the kidney can be advanced at the time of CKD diagno-
sis when serum creatinine is used as the primary diagnostic criterion.
Additionally, to what extent urinary aTGF-β1 concentration repre-
sents the renal activity of this cytokine remains unknown.
Conclusions
No signiﬁcant difference was found between cats with differ-
ing degrees of renal function in the cross-sectional study, but urinary
aTGF-β1 increased prior to documented deterioration of renal func-
tion in healthy cats that developed CKD in the longitudinal analysis.
Additionally, urinary aTGF-β1 correlated with histopathological ev-
idence of renal inﬂammation and interstitial ﬁbrosis. These results
suggest that urinary aTGF-β1 reﬂects the severity of renal pathol-
ogy and that urinary aTGF-β1 followed longitudinally in an individual
cat may be a surrogate marker of active renal ﬁbrosis and chronic
inﬂammation that could lead to the development of CKD.
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